Can a standardized MRI accurately stage esophageal cancer?
NCT ID NCT07769658
First seen Aug 18, 2026 · Last updated Aug 18, 2026
Summary
This trial aims to develop and validate a standardized MRI protocol for staging esophageal squamous cell carcinoma and assessing how well tumors respond to neoadjuvant therapy. About 500 adults scheduled for surgery will be enrolled, with some undergoing MRI before surgery and others before and after treatment. The MRI results will be compared with the actual tumor pathology to see if the imaging can reliably determine the extent of the cancer and the degree of regression after therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Standardized 3.0-T esophageal magnetic resonance imaging (MRI) protocol
- What this could lead to
- If successful, this could establish a reliable, non-invasive imaging standard for staging esophageal cancer and evaluating treatment response, potentially reducing the need for invasive procedures.
- What could go wrong
- The trial is diagnostic and exploratory, with accuracy dependent on image quality and reader expertise. MRI may not perfectly match pathological findings, and results may vary across centers and equipment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
-
Henan Provincial Chest Hospital (Zhengzhou University Affiliated Chest Hospital)
Zhengzhou, Henan, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, China
-
Yunnan Cancer Hospital
Kunming, Yunnan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- AI biomarker may reveal who responds to esophageal cancer immunotherapy
- Can a single Protein's mutations predict esophageal cancer outcomes?
- A sponge you swallow could detect esophageal cancer before it spreads